Top

Quality of Life Research

Gepubliceerd in:

13-02-2023

Statin withdrawal and health-related quality of life in a primary cardiovascular prevention cohort

Auteurs: P. Peyrel, P. Mauriège, J. Frenette, N. Laflamme, K. Greffard, C. Huth, J. Bergeron, D. R. Joanisse

Gepubliceerd in: Quality of Life Research | Uitgave 7/2023

Abstract

Purpose

While some work has been done on Health-Related Quality of Life (HRQoL) in statin users, none has focused specifically on statin-associated muscle symptoms (SAMS) sufferers. The objective was to assess self-reported HRQoL, before and after statin withdrawal, in patients reporting SAMS. We hypothesized that the presence of SAMS associated with decreased self-reported physical and mental well-being.

Methods

Patients (50 men/28 women [M/W], aged 49 ± 9 years [Mean ± SD]) in primary cardiovascular prevention were recruited into three cohorts: statin users with (SAMS, 29 M/18W) or without symptoms (No SAMS, 10 M/5W) and controls (11 M/5W). The Short Form 36 Health Survey (SF-36) was used to assess HRQoL. All variables were measured before and after 2 months of statin withdrawal, and repeated measures analyses were used to verify withdrawal and group effects as well as their interaction.

Results

SF-36 physical and mental component scores (respectively, PCS and MCS) were lower in the SAMS group compared with other groups (both p < 0.01). Statin withdrawal led to an increase in LDL cholesterol for statin users (+69.0%, p < 0.01) and an improvement in well-being in the SAMS group, other groups showing no change. A time x category interaction (p = 0.02) was seen for PCS and post hoc analyses showed that statin withdrawal improved PCS and MCS (respectively, +12.5% [ES 0.77] and +5.1% [ES 0.27], both p < 0.05) in the SAMS group.

Conclusion

Patients self-reporting SAMS showed improved HRQoL following drug withdrawal, but this was mirrored by a rise in LDL cholesterol. These findings should be considered by clinicians in the evaluation and follow-up of treatment with statins.

vorige artikel Quantifying health-related quality of life in Malaysian type 2 diabetes: focusing on complication types and severity

volgende artikel Prevalence of musculoskeletal complaints and health-related quality of life in a Maroon and Kalinya Indigenous rural village in Suriname

Alleen toegankelijk voor geautoriseerde gebruikers

Cohen, J. D., Brinton, E. A., Ito, M. K., & Jacobson, T. A. (2012). Understanding Statin use in America and gaps in patient Education (USAGE): an internet-based survey of 10138 current and former statin users. Journal of Clinical Lipidology, 6(3), 208–215. https://doi.org/10.1016/j.jacl.2012.03.003CrossRefPubMed

Sivashanmugarajah, A., Fulcher, J., Sullivan, D., Elam, M., Jenkins, A., & Keech, A. (2019). Suggested clinical approach for the diagnosis and management of ‘statin intolerance’ with an emphasis on muscle-related side-effects. Internal Medicine Journal, 49(9), 1081–1091. https://doi.org/10.1111/imj.14429CrossRefPubMed

Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M., Jr., Kastelein, J. J., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., Nordestgaard, B. G., Shepherd, J., Willerson, J. T., & Glynn, R. J. (2008). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine, 359(21), 2195–2207. https://doi.org/10.1056/NEJMoa0807646CrossRefPubMed

Thompson, P. D., Panza, G., Zaleski, A., & Taylor, B. (2016). Statin-associated side effects. Journal of the American College of Cardiology, 67(20), 2395–2410. https://doi.org/10.1016/j.jacc.2016.02.071CrossRefPubMed

Wagstaff, L. R., Mitton, M. W., Arvik, B. M., & Doraiswamy, P. M. (2003). Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 23(7), 871–880. https://doi.org/10.1592/phco.23.7.871.32720CrossRef

Bruckert, E., Hayem, G., Dejager, S., Yau, C., & Begaud, B. (2005). Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients–the PRIMO study. Cardiovascular Drugs and Therapy, 19(6), 403–414. https://doi.org/10.1007/s10557-005-5686-zCrossRefPubMed

Selva-O’Callaghan, A., Alvarado-Cardenas, M., Pinal-Fernandez, I., Trallero-Araguas, E., Milisenda, J. C., Martinez, M. A., Marin, A., Labrador-Horrillo, M., Juarez, C., & Grau-Junyent, J. M. (2018). Statin-induced myalgia and myositis: An update on pathogenesis and clinical recommendations. Expert Review of Clinical Immunology, 14(3), 215–224. https://doi.org/10.1080/1744666X.2018.1440206CrossRefPubMedPubMedCentral

Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgozoglu, L., Nordestgaard, B. G., Bruckert, E., De Backer, G., Krauss, R. M., Laufs, U., Santos, R. D., Hegele, R. A., Hovingh, G. K., Leiter, L. A., Mach, F., … P European Atherosclerosis Society Consensus. (2015). Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis Society consensus panel statement on assessment aetiology and management. European Heart Journal, 36(17), 1012–1022. https://doi.org/10.1093/eurheartj/ehv043CrossRefPubMedPubMedCentral

Bouitbir, J., Sanvee, G. M., Panajatovic, M. V., Singh, F., & Krahenbuhl, S. (2020). Mechanisms of statin-associated skeletal muscle-associated symptoms. Pharmacological Research, 154, 104201. https://doi.org/10.1016/j.phrs.2019.03.010CrossRefPubMed

10.

Taylor, B. A., & Thompson, P. D. (2018). Statin-associated muscle disease: Advances in diagnosis and management. Neurotherapeutics, 15(4), 1006–1017. https://doi.org/10.1007/s13311-018-0670-zCrossRefPubMedPubMedCentral

11.

Turner, R. M., & Pirmohamed, M. (2019). Statin-related myotoxicity: A comprehensive review of pharmacokinetic, pharmacogenomic and muscle components. Journal of Clinical Medicine, 9, 1. https://doi.org/10.3390/jcm9010022CrossRef

12.

Blacher, J., Bruckert, E., Farnier, M., Ferrieres, J., Henry, P., Krempf, M., & Mourad, J. J. (2019). Myalgia and statins: Separating the true from the false. La Presse Médicale, 48(10), 1059–1064. https://doi.org/10.1016/j.lpm.2019.07.034. (Myalgies et statines : demeler le vrai du faux.).CrossRefPubMed

13.

Hauser, W., Hansen, E., & Enck, P. (2012). Nocebo phenomena in medicine: their relevance in everyday clinical practice. Deutsches Ärzteblatt international, 109(26), 459–465. https://doi.org/10.3238/arztebl.2012.0459CrossRefPubMedPubMedCentral

14.

Pedro-Botet, J., Climent, E., & Benaiges, D. (2019). Muscle and statins from toxicity to the nocebo effect. Expert Opinion on Drug Safety, 18(7), 573–579. https://doi.org/10.1080/14740338.2019.1615053CrossRefPubMed

15.

Robinson, J. G. (2019). New insights into managing symptoms during statin therapy. Progress in Cardiovascular Diseases, 62(5), 390–394. https://doi.org/10.1016/j.pcad.2019.10.005CrossRefPubMed

16.

Alonso, R., Cuevas, A., & Cafferata, A. (2019). Diagnosis and management of statin intolerance. Journal of Atherosclerosis and Thrombosis, 26(3), 207–215. https://doi.org/10.5551/jat.RV17030CrossRefPubMedPubMedCentral

17.

Rosenson, R. S., Miller, K., Bayliss, M., Sanchez, R. J., Baccara-Dinet, M. T., Chibedi-De-Roche, D., Taylor, B., Khan, I., Manvelian, G., White, M., & Jacobson, T. A. (2017). The statin-associated muscle symptom clinical index (SAMS-CI): Revision for clinical use, content validation, and inter-rater reliability. Cardiovascular Drugs and Therapy, 31(2), 179–186. https://doi.org/10.1007/s10557-017-6723-4CrossRefPubMedPubMedCentral

18.

Carlsson, C. M., Papcke-Benson, K., Carnes, M., McBride, P. E., & Stein, J. H. (2002). Health-related quality of life and long-term therapy with pravastatin and tocopherol (vitamin E) in older adults. Drugs & aging, 19(10), 793–805. https://doi.org/10.2165/00002512-200219100-00008CrossRef

19.

Hyttinen, L., Kekalainen, P., Vuorio, A. F., Sintonen, H., & Strandberg, T. E. (2008). Health-related quality of life in elderly patients with familial hypercholesterolemia. International Journal Of Technology Assessment In Health Care, 24(2), 228–234. https://doi.org/10.1017/S0266462308080318CrossRefPubMed

20.

Mohler, E. R., 3rd., Hiatt, W. R., & Creager, M. A. (2003). Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation, 108(12), 1481–1486. https://doi.org/10.1161/01.CIR.0000090686.57897.F5CrossRefPubMed

21.

Solberg, O. G., Stavem, K., Ragnarsson, A., Beitnes, J. O., Skårdal, R., Seljeflot, I., Ueland, T., Aukrust, P., Gullestad, L., & Aaberge, L. (2019). Index of microvascular resistance to assess the effect of rosuvastatin on microvascular function in women with chest pain and no obstructive coronary artery disease: A double-blind randomized study. Catheterization and Cardiovascular Interventions, 94(5), 660–668. https://doi.org/10.1002/ccd.28157CrossRefPubMed

22.

Strandberg, T. E., Urtamo, A., Kahara, J., Strandberg, A. Y., Pitkala, K. H., & Kautiainen, H. (2018). Statin treatment is associated with a neutral effect on health-related quality of life among community-dwelling octogenarian men: The helsinki businessmen study. The Journals of Gerontology: Series A, 73(10), 1418–1423. https://doi.org/10.1093/gerona/gly073CrossRef

23.

van Boheemen, L., Tett, S. E., Sohl, E., Hugtenburg, J. G., van Schoor, N. M., & Peeters, G. M. (2016). Associations between statin use and physical function in older adults from the Netherlands and Australia: longitudinal aging study Amsterdam and Australian longitudinal study on women’s health. Drugs Aging., 33(6), 437–445. https://doi.org/10.1007/s40266-016-0370-5CrossRefPubMed

24.

Downs, J. R., Oster, G., & Santanello, N. C. (1993). HMG CoA reductase inhibitors and quality of life. JAMA, 269(24), 3107–3108. https://doi.org/10.1001/jama.1993.03500240051020CrossRefPubMed

25.

Cham, S., Evans, M. A., Denenberg, J. O., & Golomb, B. A. (2010). Statin-associated muscle-related adverse effects: A case series of 354 patients. Pharmacotherapy, 30(6), 541–553. https://doi.org/10.1592/phco.30.6.541CrossRefPubMedPubMedCentral

26.

Evans, M. A., & Golomb, B. A. (2009). Statin-associated adverse cognitive effects: Survey results from 171 patients. Pharmacotherapy, 29(7), 541–553. https://doi.org/10.1592/phco.29.7.800CrossRef

27.

Bhardwaj, S., Selvarajah, S., & Schneider, E. B. (2013). Muscular effects of statins in the elderly female: A review. Clinical Interventions in Aging, 8, 47–59. https://doi.org/10.2147/CIA.S29686CrossRefPubMedPubMedCentral

28.

Phillips, P. S., Haas, R. H., Bannykh, S., Hathaway, S., Gray, N. L., Kimura, B. J., Vladutiu, G. D., & England, J. D. F. (2002). Statin-associated myopathy with normal creatine kinase levels. Annals of Internal Medicine, 137(7), 581–585. https://doi.org/10.7326/0003-4819-137-7-200210010-00009CrossRefPubMed

29.

Leplège, A., Ecosse, E., Coste, J., Pouchot, J., & Perneger, T. (2001). Le questionnaire MOS SF-36: manuel de l’utilisateur et guide d’interprétation des scores. Éditions ESTEM.

30.

Ware, J. E., & Gandek, B. (1998). Overview of the SF-36 health survey and the international quality of life assessment (IQOLA) project. Journal of Clinical Epidemiology, 51(11), 903–912. https://doi.org/10.1016/s0895-4356(98)00081-xCrossRefPubMed

31.

Ware, J. E., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30(6), 473–483.CrossRefPubMed

32.

Ware, J. E., Kosinski, M., & Keller, S. D. (1994). SF-36 Physical and Mental Health Summary Scales: A Users’ Manual. The Health Institute.

33.

Riesco, E., Tessier, S., Pérusse, F., Turgeon, S., Tremblay, A., Weisnagel, J., Doré, J., & Mauriège, P. (2010). Impact of walking on eating behaviors and quality of life of premenopausal and early postmenopausal obese women. Menopause, 17(3), 529–538. https://doi.org/10.1097/gme.0b013e3181d12361CrossRefPubMed

34.

Ware, J. E., & Kosinski, M. (2001). Interpreting SF-36 summary health measures: a response. Quality of Life Research, 10(5), 405–413. https://doi.org/10.1023/a:1012588218728. discussion 415-420.CrossRefPubMed

35.

Add-Ins, J. (2014). Full Factorial Repeated Measures ANOVA Add-In. Retrieved 11/11 from https://community.jmp.com/t5/JMP-Add-Ins/Full-Factorial-Repeated-Measures-ANOVA-Add-In/ta-p/23904?trMode=source

36.

Berent, T., Berent, R., Steiner, S., & Sinzinger, H. (2019). Statin-induced muscular side effects at rest and exercise—An anatomical mapping. Atherosclerosis Supplements, 40, 73–78. https://doi.org/10.1016/j.atherosclerosissup.2019.08.026CrossRefPubMed

37.

Finegold, J. A., Manisty, C. H., Goldacre, B., Barron, A. J., & Francis, D. P. (2014). What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. European journal of preventive cardiology, 21(4), 464–474. https://doi.org/10.1177/2047487314525531CrossRefPubMed

38.

Gupta, A., Thompson, D., Whitehouse, A., Collier, T., Dahlof, B., Poulter, N., Collins, R., & Sever, P. (2017). Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian cardiac outcomes trial—lipid-lowering Arm (ASCOT-LLA): A randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. The Lancet, 389(10088), 2473–2481. https://doi.org/10.1016/s0140-6736(17)31075-9CrossRef

39.

Howard, J. P., Wood, F. A., Finegold, J. A., Nowbar, A. N., Thompson, D. M., Arnold, A. D., Rajkumar, C. A., Connolly, S., Cegla, J., Stride, C., Sever, P., Norton, C., Thom, S. A. M., Shun-Shin, M. J., & Francis, D. P. (2021). Side effect patterns in a crossover trial of statin, placebo, and no treatment. Journal of the American College of Cardiology, 78(12), 1210–1222. https://doi.org/10.1016/j.jacc.2021.07.022CrossRefPubMedPubMedCentral

40.

Cruz, A. C., & Pedreira, M. (2020). Patient-and Family-Centered Care and Patient Safety: reflections upon emerging proximity. Revista Brasileira de Enfermagem, 73(6), e20190672. https://doi.org/10.1590/0034-7167-2019-0672CrossRefPubMed

Titel: Statin withdrawal and health-related quality of life in a primary cardiovascular prevention cohort
Auteurs: P. Peyrel
P. Mauriège
J. Frenette
N. Laflamme
K. Greffard
C. Huth
J. Bergeron
D. R. Joanisse
Publicatiedatum: 13-02-2023
Uitgeverij: Springer International Publishing
Gepubliceerd in: Quality of Life Research / Uitgave 7/2023
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-023-03362-9

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Abstract

Purpose

Methods

Results

Conclusion

Log in om toegang te krijgen

Andere artikelen Uitgave 7/2023

Quality of life and ability to work of patients with Post-COVID syndrome in relation to the number of existing symptoms and the duration since infection up to 12 months: a cross-sectional study

Independent and joint associations of cardiorespiratory fitness and weight status with health-related quality of life among Brazilian adolescents

The impact of necrotizing soft tissue infections on the lives of survivors: a qualitative study

A national survey of Iranian general population to estimate a value set for the EQ-5D-5L

Predictors of self-reported general health status in people experiencing homelessness with serious mental illness

Quantifying health-related quality of life in Malaysian type 2 diabetes: focusing on complication types and severity